Actinogen Medical Ltd has released a press release.
First patient treated in XanaCIDD Phase 2 Depression Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- R&D tax incentive rebate received
- ACW clinical biomarker study webcast presentation
- ACW announces positive Alzheimers Disease clinical results
- Actinogen FY22 Results - Accelerating Clinical Development
- ACW Appendix 4E and 2022 Annual Report
Later from Actinogen Medical
- FDA agrees to six-month Phase 2b Alzheimers Disease Trial
- Appendix 4D & Half-Year Financial Statements
- ACW AD trial amendment and Clinical Science Forum slides
- Quarterly Activity Report & Appendix 4C
- Actinogen announces $10 million rights offer
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical